In August 2018, SpringWorks and BeiGene entered into a global clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of combining BeiGene’s investigational RAF-dimer inhibitor, lifirafenib (BGB-283) with SpringWorks Therapeutics’ investigational MEK inhibitor, mirdametinib, in a range of genetically-defined solid tumors. A Phase 1b clinical trial is enrolling patients with advanced solid tumors that harbor mutations in RAS, RAF, and other MAPK pathway genes.
MapKure is a clinical-stage company created in 2019 to develop precision medicines for patients with life-threatening diseases, with an initial focus on cancer. MapKure is jointly owned by SpringWorks and BeiGene, and is developing BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations, including V600 B-RAF mutations, non-V600 B-RAF mutations and RAF fusions. These mutations and fusions have been identified in a number of solid tumors to be drivers of cancer growth, including in non-small cell lung cancer, colorectal cancer, thyroid cancer and brain tumors.
In June 2019, SpringWorks and GlaxoSmithKline entered into a global clinical collaboration agreement to conduct a Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combining SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat with GlaxoSmithKline’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), belantamab mafodotin (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma.
In January 2020, SpringWorks and Allogene entered into a clinical collaboration to conduct a Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of combining SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, with Allogene’s investigational anti-B-cell maturation antigen (BCMA) AlloCAR TTM therapy in patients with relapsed or refractory multiple myeloma.